Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1942

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 1942
---
 respectively.

Stockholders

As of April 11, 2025, the
numbers of record holders of our Common Stock and Public Warrants were 131 and 32, respectively, not including beneficial holders whose
securities are held in street name.

Dividends

We have never declared or
paid cash dividends on our capital stock. We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our
capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business,
and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment
of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and
other factors our board of directors may deem relevant.

In addition, our ability
to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt, issued preferred securities,
or any credit facility agreements.

Securities Authorized for Issuance under Equity
Compensation Plans

Information about our equity
compensation plans set forth in Item 12 of Part III of this Annual Report is incorporated herein by reference.

Recent Sales of Unregistered Equity Securities

In February 2024, May 2024
and August 2024, we issued 1,191, 2,504, and 16,139 shares of Common Stock, respectively, to an investor as commitment shares in consideration
for entering into an equity line of credit with us. The issuance of these securities was made pursuant to Section 4(a)(2) of the Securities
Act, and the rules promulgated thereunder, to an accredited investor. As of the date of this Annual Report, we have issued an aggregate
of 744,118 shares of Common Stock to such investor pursuant to the equity line of credit.

In February 2024, we issued
an aggregate of 10,039 shares of Series A Preferred Stock, at a price of $1,000 per share, initially convertible into 10,039 shares of
Common Stock at $10.00 per share, and 2,500 Preferred Warrants, resulting in aggregate consideration to us of approximately $10.0 million.
Such issuance includes 2,185 shares of Series A Preferred Stock, initially convertible into